chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a registered nurse concerning an 8 year old male with no known allergies or medical history, who on 14-JAN-1999 was vaccinated in the left arm with a first dose of Varivax (lot # 628147/1262H). There was no illness at the time of vaccination. ON 12-MAY-2006 the patient developed a breakthrough case of varicella of about 20 lesions on his trunk, arms, neck and face. The patient was seen in the physician's office but he received no treatment and he was not hospitalized. No diagnostic or lab tests were performed. Subsequently the patient recovered. There was no product quality complaint involved. Additional information is not expected.
C/o minor rash on arms & forehead within 24 hrs of receiving TDaP vaccine recommended OTC BENADRYL & hydrocortisone cream prn itching.  No swelling or respiratory symptoms.
Patient felt cold, lightheaded and had tingling sensation. Followed by chest pain and shortness of breath. Patient was transferred to stretcher for monitoring. Dose of Solumedrol 125mg was given at 13:42. Dose of Benadryl was given at 13:45. Dose of Epi-pen was given at 14:06 and patient showed some improvement. Then ambulance arrived and patient was taken to hospital.
Hospitalized (10.16-10.19);  COVID-19 positive (10.13.21);  fully vaccinated  Admission Date: 10/16/2021 Discharge Date: 10/19/2021 PROBLEM LIST COVID pneumonia COPD  BPH HLD DETAILS OF HOSPITAL STAY: HOSPITAL COURSE  an 78 y.o. male who presented with cough, shortness of breath with sputum production, diarrhea, headache who was found to be COVID 19 positive on date 10/16/21. He was treated with decadron and remdesivir, and home inhalers. He completed 4 days of remdesivir. He briefly required oxygen but was able to be weaned to room air without symptoms. He improved both clinically and in lab findings. As he remained clinically stable on RA, it was decided patient may be discharged without completion of full 5 days of remdesivir. He was discharged home in stable condition to complete decadron course.
7 year old male here today with redness and mild swelling in left arm for 2 days after immunization.  Motrin and Keflex for 10 days.  Cellulitis
Chills; Fatigue; Headache; body aches all over the body; This spontaneous case was reported by a patient family member or friend and describes the occurrence of CHILLS, FATIGUE, HEADACHE, and PAIN in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030L20A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 (Patient shared she had COVID last November) in November 2020.    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Feb-2021, the patient experienced CHILLS, FATIGUE, HEADACHE, and PAIN. The patient was treated with TYLENOL at an unspecified dose and frequency. On 05-Feb-2021, CHILLS, FATIGUE, HEADACHE, and PAIN had resolved. Not Provided.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided. This case was received via an unknown source (no reference has been entered for a health authority) on 06-Feb-2021 and was forwarded to Moderna on 08-Feb-2021.    This spontaneous case was reported by a patient family member or friend and describes the occurrence of CHILLS, FATIGUE, HEADACHE, and PAIN in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030L20A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in November 2020.    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Feb-2021, the patient experienced CHILLS, FATIGUE, HEADACHE, and PAIN. The patient was treated with TYLENOL at an unspecified dose and frequency. On 05-Feb-2021, CHILLS, FATIGUE, HEADACHE, and PAIN had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided.
Skin infection, swelling and warm at the site, redness. Is taking antibiotic.
Date/Time 5/3/21, 5:20 pm. It was patient's second dose of Pfizer vaccine, lot #EW0171. Patient received dose about 5:05 pm and called for staff at 5:20 pm stating that she felt some numbness on her lips and on her face, around her mouth. Patient denied any other symptoms, was able to speak and breathe normally and didn't display any swelling of her lips. Staff requested client remain in parking lot for another 15 minutes for observation. Staff checked on client at 5:35 pm and client stated she felt okay, the numbness had subsided.
intermittent transient episodes of lightheadedness, speech changes, numbness/dysesthesia,    forehead dysesthesias followed by word finding difficulty +/- mild confusion, at times associated with leg jerking, L sided dysesthesias, and tongue clicking, followed by a prolonged feeling of fatigue. possible absent seizures Mild incidental length-dependent sensory loss to temperature in the distal legs  irregular small amplitude twitching lower then upper extremities with varying anatomic involvement, amplitude, and frequency.  chronic light-headedness/dizziness  Brain fog Postural orthostatic tachycardia syndrome
Pt came down with rash starting at vaccine administration site.  Then spread all over body.  Rash was typical urticaria - red, raised, itchy, wheals.  Pt already had mild URI symptoms (mild cough), but no SOB or GI symptoms.  VS NL., SpO2 94%, RR 16 and unlabored.  Pt had not taken any allergy medications - urticaria was widespread and itchy.
Felt terrible all over; Bad headache; Fever; Flu like symptoms; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu like symptoms), MALAISE (Felt terrible all over), HEADACHE (Bad headache) and PYREXIA (Fever) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Feb-2021, the patient experienced INFLUENZA LIKE ILLNESS (Flu like symptoms), HEADACHE (Bad headache) and PYREXIA (Fever). On an unknown date, the patient experienced MALAISE (Felt terrible all over). At the time of the report, INFLUENZA LIKE ILLNESS (Flu like symptoms), MALAISE (Felt terrible all over), HEADACHE (Bad headache) and PYREXIA (Fever) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication were reported No treatment medication were reported.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of these events, a causal relationship cannot be excluded.
On 10/1/2021 (patient) began dropping things due to numbness in fingers and lateral hands. Symptoms greater on right. On 10/8/2021 forearms began numbness and tingling bi-laterally. These symptoms continued until 11/23/2021 at which time patient was blanketed with numbness, tingling, burning, and pain from chest line down and through toes. Symptoms greater on right. By 11/29/2021, the numbness continued upward to include bi-lateral groins, perineum, buttock which intermittently caused patient to not feel the urge to urinate causing incontinence of urine. Upper extremity symptoms continued as well. Patient continued dropping things and symptoms worsened to include severe risk of falling. This caused patient to have to walk with a walker. On 12/6/2021 patient went to PCP APRN whom noted that Patient in lower extremities severely with numbness and tingling to the point where she could not feel them. This led her to re-call her PCP, to which APRN advised patient to go to the hospital. On 12/10/2021, the ER admitted patient into the hospital X 2 weeks with diagnosis of transverse myelitis (TM). During the 2 weeks, patient received mass dose of Steroids i.e. 1,000 mg x 5 consecutive doses. She also received Plasmapheresis x 5 treatments over 10 days. Patient was discharged home with diagnosis of TM and is on several new meds, PT and OT 3x week and numerous doctors visits. Current Status: patient is unable to walk without a walker and/or drive,  d/t bi-lateral leg burning, tingling, and pain. Patient also has difficulty picking items up and holding onto said items d/t upper extremity involvement d/t the CNS - sensory system being affected by the demyelinating lesions. Patient is at EXTREME RISK for skin injury.  Patient is at times incontinent of urine, just as she was while admitted in hospital.
High fever of 105.6F, screaming all night, wouldn't eat or drink. This occurred 3 days after vaccines. Once, fever came down, rash developed over entire body. He was sick for 2 weeks.
POSSIBLE SUNBURN; RASH ON FACE; This spontaneous report received from a patient concerned a 42 year old female. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 206A21A, and  expiry: UNKNOWN) dose was not reported, administered on 28-APR-2021 14:40 for prophylactic vaccination. No concomitant medications were reported. On 29-APR-2021, the subject experienced possible sunburn. On 29-APR-2021, the subject experienced rash on face. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from rash on face, and possible sunburn. This report was non-serious.
multi-phase anaphylaxis/several anaphylactic reactions; This is a spontaneous report from a contactable consumer (parent) from a Pfizer-sponsored program. A 17-year-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), intramuscularly in the right arm, on 17Mar2021 at 12:45 (at the age of 17-years-old) as a single dose for COVID-19 immunization. Medical history included allergies to sticking plaster (adhesive) and diabetes type 1. Family history included allergies to some antibiotics in the mother. The patient had no concomitant medications. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient experienced multi-phase anaphylaxis/several anaphylactic reactions in Mar2021, which caused hospitalization and was reported as an important medical event and life-threatening. The clinical course was reported as follows: The patient had multi-phase anaphylaxis following his first dose of vaccination. He went to three different hospitals and was in the pediatric intensive care unit (PICU) at the time of reporting. The patient was heavily sedated, intubated, and on a ventilator for 3 days. The clinical outcome of multi-phase anaphylaxis/several anaphylactic reactions was unknown.   Follow-up attempts are completed. No further information expected.
Left arm pain, followed by flu-like symptoms (fever, aches).  Most severe last night, and continuing today (had to take a sick day.  Am not yet seeking medical attention as I am expecting partial recovery tomorrow (based on my experience with the first shot)
red patches on her Knee , elbow and face , also in her back,; was very itchy; This spontaneous case was reported by a consumer and describes the occurrence of RASH (red patches on her Knee , elbow and face , also in her back,) and PRURITUS (was very itchy) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     Concurrent medical conditions included Penicillin allergy and Drug allergy (doxycycline).    On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Jan-2021, the patient experienced RASH (red patches on her Knee , elbow and face , also in her back,). 25-Jan-2021, the patient experienced PRURITUS (was very itchy). On 25-Jan-2021, RASH (red patches on her Knee , elbow and face , also in her back,) and PRURITUS (was very itchy) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not reported. Treatment details included Antihistaminic on 31Jan2021.
Diarrhea vomiting fever chills muscle aches dizziness fatigue loss of appetit. Like having extreme flu for 16 hrs. I took no medication. Sipped diet sprite and ice
pt describes onset of pain in opposite arm from inject site 1 day following vax; this pain extended from palm to shoulder on inside of arm; sx progressed to involve lt arm & both knees & lower limbs assoc w/malaise & weakness;
Dizziness, Headache, Diarrhea, Nausea Vomiting, FOGGINESS, BURNING IN ARM
Patient brought to the ED with worsening mental status and hypoxia.  Patient admitted to the hospital with Covid pneumonia and treated with remdesivir.
Received first dose of Moderna, metallic taste in mouth, awoke on 10/16/21 with dime-sized hive at injection site, by 10/18/21 hive expanded to size of quarter and was itchy, by 10/23 it grew to the size of a plum.
After receiving first Pfizer vaccine, patient had a vasovagal episode.  Patient states he became dizzy, lightheaded, and became diaphoretic prior to syncope.  There were some mild seizure-type activity after the syncope.  Patient was transferred to the ED  In the ED, patient experienced no further episodes of seizure activities.  Patient was evaluated, observed, and later discharged with PCP and neurology referral.
Soreness at the shot location in arm, nausea and stomach cramps for over a week, burping, gastrointestinal  issues, some dizziness, ear fullness on day 3/4, night sweats 3-4 days, fast heartbeat/sweating
Pt is here with c/o diffuse redness and itching rash which started last night; he took the J&J COVID vaccine around noon yesterday from facility; he denies any wheezing, dyspnea or SOB; denies any prior allergic reaction; no h/o anaphylaxis; Pt stated he was not provided with a hotline to call to reports vaccine reactions.  Solu-Cortef 100 mg IM x1 given in the office today; will also place him on prednisone taper which he will start tomorrow morning; Zyrtec 10 mg qd also started today; pt is advised to call 911 or go to the nearest ER should he developed wheezing, SOB and difficulty breathing; he agrees with plan and voices understanding. Incident about the vaccine reported to VAERS.
Patient said that about 8 days after receiving the Moderna Covid 19 vaccine she noticed that her arm had a red rash in a circular formation measuring 2 by 2 1/2 inches in diameter at the location of vaccine administration.  She said it did NOT itch nor was it painful, but she said it felt different.  She reported that the area did not seem to be changing in size, but it was getting more red.  She also reported developing a minor headache the morning after the vaccination and it lasted until noon.  The headache resolved itself and has not come back.
experienced tinnitus, hip pain, tenderness under her breast; experienced tinnitus, hip pain, tenderness under her breast; experienced tinnitus, hip pain, tenderness under her breast; Tinnitus has been louder since the vaccine/It is her left hip into the leg and a little in the butt area. It got progressively worse then it stayed the same.; She thinks they said it could be lymph nodes.; burning or tenderness in the arm pit area and in the breast on left side; pain in the hip that his radiating to the back; overall tiredness; This is a spontaneous report from a contactable consumer (Patient). A 55-years-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot Number: EN6201, Expiry date: 30Jun2021), via an unspecified route of administration (at the age of 55-years), administered in left arm on 18Feb2021 as dose 1, 0.3 ml single for COVID-19 immunization. The patient medical history and concomitant medications were not reported. Patient asked whether she could move her scheduled second dose of the bnt162b2 vaccine to a later date, what vitamins she could take after getting the second dose of the vaccine that won't interfere with the vaccine's effectivity, whether she could take TYLENOL after getting the bnt162b2 vaccine. Patient was wondering how current the information is, she supposed to get the shot next Thursday. If she wanted to move the date out five days because she has a personal commitment and doesn't want to be sick the day after. Some people say to hydrate before the vaccine. Are there any tips for the day before to prepare the body to not have such a reaction after the vaccine? No other additional vaccines administered on same date of the bnt162b2 vaccination. No prior vaccination within 4 weeks. The patient did not experience adverse events prior vaccination. On unspecified date, patient experienced, patient has tinnitus, but it has been an increase in volume. It is usually a much milder form. Tinnitus has been louder since the vaccine. Pain in the hip that his radiating to the back. Burning or tenderness in the arm pit area and in the breast on left side. It feels like a hot pinch in there sometimes. Patient thinks it could be lymph nodes. It has been two weeks; she has over all tiredness. Patient started to experience the side effects within a day or so. It was her left hip into the leg and a little in the butt area. It got progressively worse than it stayed the same. At the time of reporting, it may have gotten a little better. There were a couple of days it has been really terrible. She has been trying to rest it more. She has been a little achy, but then to get out of chair the weight hurts. She feels sore when she puts pressure on it. The outcome of the events was unknown.  No follow-up attempts are possible. No further information is expected.
Vaccine was given 9/13/2022. Vaccine expiration date was 9/9/2022.  Child had no symptoms several hours later when writer called mother with update.  No adverse reactions reported.
Rash. Ranitidine 150 mg bid, Hydroxyzine 25 mg bid.
Developed Fever 104 Rectal - Tx'd with Motrin @IZAM
I started to get itchy little bumps on bottom of my arm; This is a spontaneous report from a contactable consumer or other non hcp (patient). A 34-year-old patient of an unspecified gender received second dose of bnt162b2 (BNT162B2 PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, Batch/Lot number: UNKNOWN), via an unspecified route of administration on an unspecified date (at the age of 34-years-old) as dose 2, single for covid-19 immunisation. The medical history of the patient was reported as none. The concomitant medications of the patient were not reported. The patient previously received first dose of BNT162B2 (solution for injection) on an unspecified date as a single dose for COVID-19 immunisation. The patient experienced I started to get itchy little bumps on bottom of my arm on an unspecified date. the outcome if the events was reported as unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
received Boostrix on 5-29-2020 and accidently received another / today 8-3-2021; This case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 12-year-old male patient who received DTPa (Reduced antigen) (Boostrix) (batch number 575HC, expiry date 28th February 2023) for prophylaxis.   Co-suspect products included dtpa vaccine. pre-filled syringe device (Boostrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   Previously administered products included Boostrix (a dose received on 29th May 2020).   On 3rd August 2021, the patient received Boostrix (intramuscular) and Boostrix Pre-Filled Syringe Device. On 3rd August 2021, unknown after receiving Boostrix and Boostrix Pre-Filled Syringe Device, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The patient accidently received another Boostrix vaccine in an unknown arm on the day of reporting, which led to extra dose administered. No other details were known. The reporter consented to follow up.
This spontaneous report was received from a registered nurse and refers to an unknown number of patients of unknown age and gender. Patients' pertinent medical history and drug reactions or allergies were not reported. On unknown dates, patients were vaccinated with VARIVAX (lot number L025205 and expiration date 0-JUL-2017, lot number L042266 and expiration date 27-OCT-2017, lot number L048462 and expiration date 02-DEC-2017, lot number L048465 and expiration date 02-DEC-2017, lot number M009765 and expiration date 23-FEB-2018, dose and route of administration were not reported). Concomitant therapy was not reported. The temperature of excursion was 24.1F and the time frame was 5 hours and 41 minutes. There was no previous temperature excursion. No adverse effects were reported. No product quality complaint (PQC) was involved.  This is one of the two reports received from the same reporter. Additional information has been requested.
Vaccination site pain; Vaccination site erythema; Vaccination site swelling; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Vaccination site pain), VACCINATION SITE ERYTHEMA (Vaccination site erythema) and VACCINATION SITE SWELLING (Vaccination site swelling) in an 86-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 074C21A, 030L20A and 001A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 26-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (Vaccination site pain), VACCINATION SITE ERYTHEMA (Vaccination site erythema) and VACCINATION SITE SWELLING (Vaccination site swelling). At the time of the report, VACCINATION SITE PAIN (Vaccination site pain), VACCINATION SITE ERYTHEMA (Vaccination site erythema) and VACCINATION SITE SWELLING (Vaccination site swelling) outcome was unknown.            Concomitant medication was not reported. Treatment information was not reported.
had shingles in one of her eyes; fell; This case was reported by a consumer and described the occurrence of ophthalmic herpes zoster in a 85-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   In August 2019, the patient received the 1st dose of Shingrix. On an unknown date, 9 months after receiving Shingrix, the patient experienced ophthalmic herpes zoster (serious criteria GSK medically significant) and fall. On an unknown date, the outcome of the ophthalmic herpes zoster and fall were unknown.   It was unknown if the reporter considered the ophthalmic herpes zoster and fall to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The patient received Shingrix and shortly after that patient was fell and not able to get 2nd shot. About 9 months after the 1st shot, she had shingles in one of her eyes. Her shingles have been gone at least 3 months. The reporter queried if the patient should get the 2nd shot now or should she start over with the 1st shot and then get 2nd in a couple of months. The reporter stated the physician and pharmacist were not been able to answer and told her that she needs to get 2nd dose.